Cystic fibrosis therapeutics in major developed markets to 2019

227 views
153 views

Published on

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
227
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Cystic fibrosis therapeutics in major developed markets to 2019

  1. 1. Cystic Fibrosis Therapeutics in Major Developed Markets $4.5 billion in 2019: ResearchMoz.us ResearchMoz include new market research report" Cystic Fibrosis Therapeutics in Major Developed Markets 2019: Industry Size, Shares, Growth, Trends And Forecast 2019" to its huge collection of research reports. View Full Report at http://www.researchmoz.us/cystic-fibrosis-therapeutics-in-major-developedmarkets-to-2019-cftr-modulators-initiate-drive-towards-personalized-treatment-and-market-growthreport.html Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive Towards Personalized Treatment and Market Growth.” The value of the Cystic Fibrosis (CF) market is expected to increase significantly in value over the forecast period across the leading eight developed nations, from $695.6 million in 2012 to almost $4.5 billion in 2019. This equates to a Compound Annual Growth Rate (CAGR) of 30.4%. Novel treatments with disease-modifying mechanisms of action are the primary factor driving the growth of the value of the market. The positive impact of new market entrants will offset the effects of key patent losses during the forecast period. TABLE OF CONTENT 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Disease Introduction 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Diagnosis 2.6 Prognosis 2.7 Assessment of Disease Severity
  2. 2. 2.8 Treatment 3 Marketed Products 3.1 Overview 3.2 Product Profiles 3.2.1 Pulmozyme (dornase alfa) – Genentech 3.2.2 Bronchitol (mannitol) – Pharmaxis 3.2.3 TOBI (tobramycin) – Novartis 3.2.4 TOBI Podhaler (tobramycin) – Novartis 3.2.5 Bramitob/Bethkis (tobramycin) – Chiesi Farmaceutici 3.2.6 Colobreathe (colistimethate sodium) – Forest Laboratories 3.2.7 Cayston (aztreonam) – Gilead Sciences 3.2.8 Kalydeco (ivacaftor) – Vertex Pharmaceuticals 3.2.9 Pancreatic Enzyme Replacement Therapies 3.2.10 Other Successful Products 3.3 Heat Map of Marketed Products 3.4 Conclusion 4 Developmental Pipeline 4.1 Overview 4.2 Mechanisms of Action in the Pipeline 4.3 Clinical Trials 4.3.1 Failure Rate 4.3.2 Clinical Trial Duration 4.3.3 Clinical Trial Size 4.4 Promising Pipeline Molecules 4.4.1 Lumacaftor (VX809) – Vertex Pharmaceuticals
  3. 3. 4.4.2 Ataluren (PTC124) – PTC Therapeutics 4.4.3 Aeroquin (levofloxacin) – Aptalis Pharma 4.4.4 Arikace (amikacin liposomal) – Insmed 4.4.5 Other Promising Molecules 4.5 Heat Map of Pipeline Products 4.6 Conclusion 5 Market Forecast to 2019 5.1 Geographical Markets 5.1.1 Global Markets 5.1.2 North America 5.1.3 Top Five EU Countries 5.2 Drivers and Barriers 5.2.1 Drivers 5.2.2 Barriers 6 Strategic Consolidations 6.1 Major Co-Development Deals 6.2 Major Licensing Deals 7 Appendix 7.1 References 7.1.1 Marketed Product Heat Map References 7.1.2 Pipeline Product Heat Map References 7.2 Market Definition 7.3 Abbreviations 7.4 Methodology 7.5 Coverage
  4. 4. 7.6 Secondary Research 7.7 Therapeutic Landscape 7.8 Epidemiology-Based Forecasting 7.9 Market Size by Geography 7.10 Geographical Landscape 7.11 Pipeline Analysis 7.12 Competitive Landscape 7.12.1 Expert Panel Validation 7.13 Contact Us 7.14 Disclaimer List of Tables Table 1: Cystic Fibrosis Market, Global, Treatment Plan Table 2: Cystic Fibrosis Market, Global, Pipeline, Preclinical Table 3: Cystic Fibrosis Market, Global, Pipeline, Phase I Table 4: Cystic Fibrosis Market, Global, Pipeline, Phase II Table 5: Cystic Fibrosis Market, Global, Pipeline, Phase III Table 6: Cystic Fibrosis Market, Global, Pipeline, Pre-Registration Table 7: Cystic Fibrosis Market, Global, Pipeline, Undisclosed Table 8: Cystic Fibrosis Market, Global, Market Forecast, 2012-2019 Table 9: Cystic Fibrosis Market, US, Market Forecast, 2012-2019 Table 10: Cystic Fibrosis Market, Canada, Market Forecast, 2012-2019 Table 11: Cystic Fibrosis Market, UK, Market Forecast, 2012-2019 Table 12: Cystic Fibrosis Market, France, Market Forecast, 2012-2019 Table 13: Cystic Fibrosis Market, Germany, Market Forecast, 2012-2019 Table 14: Cystic Fibrosis Market, Italy, Market Forecast, 2012-2019
  5. 5. Table 15: Cystic Fibrosis Market, Spain, Market Forecast, 2012-2019 List of Figures Figure 1: Cystic Fibrosis Market, Global, Marketed, Heat Map Figure 2: Cystic Fibrosis Market, Global, Pipeline Summary Figure 3: Cystic Fibrosis Market, Global, Pipeline Mechanisms of Action Figure 4: Cystic Fibrosis Market, Global, Clinical Trial Failure Rate Figure 5: Cystic Fibrosis Market, Global, Pipeline Trial Duration Figure 6: Cystic Fibrosis Market, Global, Pipeline, Trial Duration by Mechanism of Action Figure 7: Cystic Fibrosis Market, Global, Pipeline Trial Size Figure 8: Cystic Fibrosis Market, Global, Pipeline, Trial Size by Mechanism of Action Figure 9: Cystic Fibrosis Market, Global, Pipeline, Promising Pipeline Products, Lumacaftor Forecast, 2015-2019 Figure 10: Cystic Fibrosis Market, Global, Pipeline, Promising Pipeline Products, Ataluren Forecast, 2016-2019 Figure 11: Cystic Fibrosis Market, Global, Pipeline Promising Pipeline Products, Aeroquin Forecast, 2014-2019 Figure 12: Cystic Fibrosis Market, Global, Pipeline, Promising Pipeline Products, Arikace Forecast, 2015-2019 Figure 13: Cystic Fibrosis Market, Global, Pipeline, Heat Map Figure 14: Cystic Fibrosis Market, Global, Treatment Patterns, 2012–2019 Figure 15: Cystic Fibrosis Market, Global, Market Size, 2012–2019 Figure 16: Cystic Fibrosis Market, North America, Treatment Patterns, 2012–2019 Figure 17: Cystic Fibrosis Market, North America, Annual Cost of Treatment, 2012–2019 Figure 18: Cystic Fibrosis Market, North America, Market Size, 2012–2019 Figure 19: Cystic Fibrosis Market, Top Five EU Countries, Treatment Patterns, 2012–2019
  6. 6. Figure 20: Cystic Fibrosis Market, Top Five EU Countries, Annual Cost of Treatment, 2012–2019 Figure 21: Cystic Fibrosis Market, Top Five EU Countries, Market Size, 2012–2019 Figure 22: Cystic Fibrosis Market, Global, Major Co-developments by Region and Value, 2006–2013 Figure 23: Cystic Fibrosis Market, Global, Major Co-development Deals by Year, 2006–2013 Figure 24: Cystic Fibrosis Market, Global, Co-development Deals by Phase, 2006–2013 Figure 25: Cystic Fibrosis Market, Global, Licensing Deals by Region, 2006–2013 Figure 26: Cystic Fibrosis Market, Global, Licensing Deals by Year, 2006–2013 Figure 27: Cystic Fibrosis Market, Global, Licensing Deals by Phase, 2006–2013 Figure 28: Forecasting Model for Therapeutic Areas V View Full Report at http://www.researchmoz.us/cystic-fibrosis-therapeutics-in-major-developedmarkets-to-2019-cftr-modulators-initiate-drive-towards-personalized-treatment-and-market-growthreport.html About ResearchMoz ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. For More Information Kindly Contact: Website@ http://www.researchmoz.us/ Email: sales@researchmoz.us Browse Blog - http://pramoddige91.wordpress.com/

×